Legato Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Legato Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,960	Closed	-$321K	–	774
2026 Q1	$321K	Buy	+15,960	New	+$257K	0.03%	619
2024 Q3	–	Sell	-23,674	Closed	-$279K	–	602
2024 Q2	$279K	Hold	23,674	–	–	0.04%	495
2024 Q1	$281K	Buy	+23,674	New	+$316K	0.03%	514
2021 Q3	–	Sell	-12,903	Closed	-$309K	–	262
2021 Q2	$309K	Buy	+12,903	New	+$338K	0.04%	321

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Legato Capital Management's KALV Position: Q2 2026 in Review

Legato Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 15,960 shares — an estimated $321K sold.

Legato Capital Management first reported a position in KALV in Q2 2021 and held it in 4 quarters. The position peaked at $321K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Legato Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Legato Capital Management sold 15,960 KalVista Pharmaceuticals shares in Q2 2026, an estimated $321K.
Legato Capital Management first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Legato Capital Management's KalVista Pharmaceuticals position peaked at $321K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.